Provided is an additive for imparting ultraviolet absorbency, or an additive for imparting a high refractive index, which has satisfactory compatibility with a resin serving as a matrix and can maintain high transparency even if added in high concentrations. Also provided is an additive with which the function of imparting both ultraviolet absorbency and a high refractive index can be realized by means of one kind of additive. This additive is represented by the following Formula (I): ##STR00001## wherein at least one of R.sup.1a to R.sup.9a is a monovalent sulfur-containing group represented by the following Formula (i-1) or Formula (i-2):
R.sup.10a.sub.mSH  (i-1)
R.sup.11a.sub.nSR.sup.12a—S.sub.pR.sup.13a  (i-2) wherein R.sup.10a to R.sup.12a each represent a divalent hydrocarbon group or the like; and R.sup.13a represents a monovalent hydrocarbon group or the like.

According to the present invention, there is provided a method of producing a salt, including reacting M.sup.+X.sup.− with YH to generate XH and M.sup.+Y.sup.− and subsequently removing the generated XH to obtain the M.sup.+Y.sup.−.

In the method of producing a salt, M.sup.+X.sup.− is a salt of a cation represented by M.sup.+ and an anion represented by X.sup.−, M.sup.+Y.sup.− is a salt of the cation represented by M.sup.+ and an anion represented by Y.sup.−, XH is a conjugate acid of X.sup.−, YH is a conjugate acid of Y.sup.−, M.sup.+Y.sup.− is a compound that generates an acid upon irradiation with an active ray or a radioactive ray, a pKa of XH is larger than a pKa of YH, and a ClogP value of XH is larger than 2.

According to the present invention, there is provided a method of producing a salt, including reacting M.sup.+X.sup.− with YH to generate XH and M.sup.+Y.sup.− and subsequently removing the generated XH to obtain the M.sup.+Y.sup.−.

In the method of producing a salt, M.sup.+X.sup.− is a salt of a cation represented by M.sup.+ and an anion represented by X.sup.−, M.sup.+Y.sup.− is a salt of the cation represented by M.sup.+ and an anion represented by Y.sup.−, XH is a conjugate acid of X.sup.−, YH is a conjugate acid of Y.sup.−, M.sup.+Y.sup.− is a compound that generates an acid upon irradiation with an active ray or a radioactive ray, a pKa of XH is larger than a pKa of YH, and a ClogP value of XH is larger than 2.

The disclosure provides recording materials including aromatic substituted alkane-core derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. Several structures are disclosed, including Formula I. When used in Bragg gratings applications, the monomers and polymers disclosed lead to materials with higher refractive index, low birefringence, and high transparency. The disclosed derivatized monomers and polymers can be used in any volume Bragg gratings materials, including two-stage polymer materials where a matrix is cured in a first step, and then the volume Bragg grating is written by way of a second curing step of a monomer.

The disclosure provides recording materials including aromatic substituted alkane-core derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. Several structures are disclosed, including Formula I. When used in Bragg gratings applications, the monomers and polymers disclosed lead to materials with higher refractive index, low birefringence, and high transparency. The disclosed derivatized monomers and polymers can be used in any volume Bragg gratings materials, including two-stage polymer materials where a matrix is cured in a first step, and then the volume Bragg grating is written by way of a second curing step of a monomer.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

##STR00001##

A process synthesizes a compound with at least one alkylene group and at least one thiol or thiolate group. The process involves reacting a compound with at least one five-membered cyclic monothiocarbonate group with a starter selected from a compound with at least one thiol group, from a compound with at least one hydroxy group, or from a basic inorganic composed; to obtain a compound with at least one alkylene group and at least one thiol or thiolate group and carbon dioxide.

A process synthesizes a compound with at least one alkylene group and at least one thiol or thiolate group. The process involves reacting a compound with at least one five-membered cyclic monothiocarbonate group with a starter selected from a compound with at least one thiol group, from a compound with at least one hydroxy group, or from a basic inorganic composed; to obtain a compound with at least one alkylene group and at least one thiol or thiolate group and carbon dioxide.

The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.